Compare · AYLA vs HWKN
AYLA vs HWKN
Side-by-side comparison of Ayala Pharmaceuticals Inc. (AYLA) and Hawkins Inc. (HWKN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AYLA and HWKN operate in Specialty Chemicals (Consumer Discretionary), so they compete in similar markets.
- HWKN is the larger of the two at $3.30B, about 44.0x AYLA ($75.1M).
- HWKN has more recent analyst coverage (6 ratings vs 5 for AYLA).
- Company
- Ayala Pharmaceuticals Inc.
- Hawkins Inc.
- Price
- $0.56+11.00%
- $158.44+0.98%
- Market cap
- $75.1M
- $3.30B
- 1M return
- -
- -2.23%
- 1Y return
- -
- +15.73%
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 0
- Recent ratings
- 5
- 6
Ayala Pharmaceuticals Inc.
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Hawkins Inc.
Hawkins, Inc. blends, manufactures, and distributes chemicals and other specialty ingredients in the United States and internationally. It operates through three segments: Industrial, Water Treatment, and Health and Nutrition. The Industrial segment offers industrial chemicals, products, and services to agriculture, chemical processing, electronics, energy, food, pharmaceutical, and plating industries. This segment primarily provides acids, alkalis, and industrial and food-grade salts. It also receives, stores, and distributes various chemicals, such as liquid caustic soda, sulfuric acid, hydrochloric acid, urea, phosphoric acid, aqua ammonia, and potassium hydroxide. In addition, this segment manufactures sodium hypochlorite and agricultural products, as well as various food-grade products that include liquid phosphates, lactates, and other blended products; repackages water treatment chemicals and bulk industrial chemicals; and performs custom blending of chemicals, and contract and private label bleach packaging. The Water Treatment segment offers chemicals, equipment, and solutions for potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool and agriculture water. The Health and Nutrition segment offers ingredient distribution, processing, and formulation solutions to manufacturers of nutraceutical, functional food and beverage, personal care, dietary supplement and other nutritional food, and health and wellness products. Its products portfolio includes minerals, botanicals and herbs, vitamins and amino acids, excipients, joint products, sweeteners, and enzymes. The company was founded in 1938 and is headquartered in Roseville, Minnesota.
Latest AYLA
- SEC Form 3 filed by new insider Martell Bridget A
- SEC Form 3 filed by new insider Orbach Pini
- SEC Form 3 filed by new insider Golan Roy
- SEC Form 10-K filed by Ayala Pharmaceuticals Inc.
- SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)
- SEC Form SC 13G filed by Ayala Pharmaceuticals Inc.
- SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)
- SEC Form 15-12G filed by Ayala Pharmaceuticals Inc.
- Ayala Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets
- SEC Form 4: Amoon Growth Fund Limited Partnership returned 2,991,473 shares to the company
Latest HWKN
- New insider Louismet Dan claimed ownership of 6 shares (SEC Form 3)
- Hawkins Inc. filed SEC Form 8-K: Leadership Update
- VP HEALTH AND NUTRITION Rozeboom Shirley A. covered exercise/tax liability with 3,608 shares and was granted 1,906 shares, decreasing direct ownership by 4% to 34,088 units (SEC Form 4)
- VP - WATER TREATMENT GROUP Lange Douglas A. was granted 1,994 shares, increasing direct ownership by 8% to 27,147 units (SEC Form 4)
- EXECUTIVE VP AND CFO Oldenkamp Jeffrey P. was granted 8,435 shares, increasing direct ownership by 9% to 102,818 units (SEC Form 4)
- VICE PRESIDENT OF OPERATIONS Grahek Drew M. was granted 2,697 shares, increasing direct ownership by 8% to 37,136 units (SEC Form 4)
- VP-INDUSTRIAL SOLUTIONS GROUP Mangine David J. was granted 1,906 shares, increasing direct ownership by 7% to 27,763 units (SEC Form 4)
- VP of Food and Health Sciences Jones Gregory Alan was granted 1,970 shares, increasing direct ownership by 24% to 10,144 units (SEC Form 4)
- CEO AND PRESIDENT Hawkins Patrick H. was granted 16,934 shares, increasing direct ownership by 6% to 321,726 units (SEC Form 4)
- SEC Form 10-K filed by Hawkins Inc.